AUTHORS
Guanhua Hu, PhD, Yingxi Zuo2, Feng Zhang3, Huifang Wang4, Pan Suo5, Lu Bai6, Yuqian Sun7, Yu Wang8, Lanping Xu, MD9, Xiaohui Zhang, MD10, Yifei Cheng11, Xiaojun Huang, MD, PhD12
AFFILIATIONS
1 Peking University People's Hospital, Beijing, China
2 Peking University People's Hospital, Beijing, China
3 Peking University People's Hospital, Beijing, China
4 Peking University People's Hospital, Beijing, China
5 Peking University People's Hospital, Beijing, China
6 Peking University People's Hospital, Beijing, China
7 Peking University People's Hospital, Beijing, China
8 Peking University People's Hospital, Beijing, China
9 Peking University People's Hospital, Beijing, China
10 Peking University People's Hospital, Beijing, China
11 Peking University People's Hospital, Beijing, China
12 Peking University People's Hospital, Beijing, China
ABSTRACT
Introduction
Children with refractory/relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL) relapse frequently, and have poor outcomes even after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and effective post-transplant maintenance strategies is lacking. We assessed the efficacy, safety and impact on immune reconstitution of blinatumomab maintenance therapy.
Methods
This prospective, single-center clinical study enrolled 10 children with R/R B-ALL who underwent allo-HSCT at Peking University People's Hospital (June 2024–September 2025). Eligible patients were 0–18 years, in ≥CR2 pre-transplant with high-risk features, no morphologic remission pre-transplant, MRD/PCR positivity pre-transplant, or within 100 days post-transplant. Blinatumomab was administered at 3 or 9 months posttransplant per 28-day cycle by weight-based step-dose (≥45 kg; 9 μg/d for 1-7 days, 28 μg/day for 8-28 days; <45 kg: 5 and 15 μg/m²/d, respectively). All received myeloablative conditioning with standard GVHD prophylaxis. The primary endpoint was the 1-year CIR; secondary endpoints included OS, EFS, treatment-related mortality, and AEs. Kaplan–Meier estimated survival outcomes.
Results
The 10 patients (median age 8 years; 5 male, 5 female) were all MRD-negative and in morphologic remission (9 CR2, 1 CR3); 4 had extramedullary involvement (3 CNS leukemia) and 7 adverse molecular-cytogenetic markers. Nine received haploidentical HSCT, and 1 matched sibling donor HSCT. Nine (90%) completed ≥1 cycle of blinatumomab, and one (10%) completed two. CRS occurred in five (50%), all grade 1–2 with no grade ≥3. Other AEs were grade 4 neutropenia in (1;10%), grade 3 alanine aminotransferase elevation (1;10%), and a grade <3 (grade 1–2) pulmonary infection (1;10%). Chronic graft-versus host-disease (cGVHD) occurred in 3 (30%), all mild. After a median follow-up of 14.8 (9-24) months, 1 relapsed, yielding a 1-year CIR of 10%, EFS of 90%, and an OS of 100%. Immune reconstitution analyses demonstrated gradual recovery of CD3+T cells, CD4+T cells, CD8+T cells, and CD19+B cells over time. CD19+B cell counts decreased transiently during blinatumomab therapy and gradually recovered after discontinuation.
Conclusion
Blinatumomab maintenance after allo-HSCT appears safe and feasible in children with R/R B-ALL, with manageable AEs, no acute GVHD, no treatment-related mortality, and no rise in infection or GVHD risk. It may reduce relapse and improve long-term prognosis. Larger, multicenter studies with longer follow-up are needed to confirm these findings.
Keywords: Allogeneic hematopoietic stem cell transplantation; Childhood B-cell acute lymphoblastic leukemia; Maintenance therapy; Blinatumomab
DISCLOSURES
Guanhua Hu, PhD: No relevant conflicts of interest to declare.